Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA RCT) (HEAL-FHA)
A Digital Psychoeducational Self-help Program Versus Usual Care to Restore Ovulatory Menstrual Cycles in Women With Functional Hypothalamic Amenorrhea: a Randomized Controlled Trial (HEAL-FHA RCT)
The goal of this clinical trial is to learn whether a 10-week digital psychoeducational health and lifestyle program can help women with functional hypothalamic amenorrhea (FHA) recover ovulatory menstrual cycles and endocrine function.
The main questions the study aims to answer are:
Does the program increase the proportion of women who have at least one spontaneous ovulatory menstrual cycle within 12 months? Does it improve hormonal markers of recovery of the hypothalamic-pituitary-ovarian axis, such as LH, FSH, estradiol and T3? Does it improve psychological well-being, stress and eating-related symptoms?
Researchers will compare the program with usual care to see whether the structured program leads to faster or more frequent recovery of menstrual and endocrine function than the care women typically receive today.
Participants will:
Be randomly assigned to the 10-week digital self-help program, delivered via the Swedish healthcare platform 1177 with one module per week (intervention group), or to usual care with a consultation with a gynecologist (comparison group); the comparison group is offered the program after the study Complete questionnaires and a structured diagnostic interview Provide blood samples to measure hormone levels at 3, 6, 9 and 12 months Contact the clinic if menstrual bleeding occurs, so that a blood sample can confirm ovulation Have a gynecological examination with ultrasound after 12 months to assess ovarian activity and endometrial thickness
This study builds on an ongoing feasibility study (NCT07589868) and will help determine whether the program is effective and should be offered more widely to women with FHA.
研究概览
详细说明
The study is a randomized, controlled trial with multicentre recruitment evaluating a 10-week digital psychoeducational health and lifestyle program with 12 months of follow-up in women with functional hypothalamic amenorrhea (FHA).
Background and Significance FHA is a functional endocrine condition that can be reversed through behavioural and lifestyle changes. A structured psychoeducational program may support these changes by improving knowledge, motivation and self-management skills. The program is compared with usual care to determine whether it leads to superior restoration of ovulatory menstrual cycles and endocrine function.
Study Aim To evaluate whether a 10-week digital psychoeducational program, compared with usual care, increases the proportion of women with FHA who recover spontaneous ovulatory menstrual cycles within 12 months.
Study Setting and Participants Seventy women aged 18-40 years with FHA (amenorrhea for ≥3 months and with a hypothalamic hormone profile: FSH <10 IU/L, LH <10 IU/L and estradiol <200 pmol/L after exclusion of other causes of amenorrhea) are recruited through several gynecological clinics, with central coordination at Karolinska University Hospital. Individuals who meet exclusion criteria receive appropriate clinical information, standard care or referral to relevant healthcare services.
Intervention and Comparator The intervention is a 10-week self-help program delivered via the Swedish healthcare platform 1177 (Stöd och behandling) with one module per week and no therapist support. The comparison group receives usual care, including a consultation with a gynecologist with standard information about FHA, and is offered the program after the 12-month follow-up.
Sample Size In the only previous randomized trial (Berga et al. 2003), ovarian activity recovered in 87.5% of women receiving individual cognitive behavioural therapy compared with 25% with observation. Because small trials tend to overestimate effects, and because the present intervention is a digital self-help program with a stricter primary outcome, a difference of 60% versus 25% is assumed. With 80% power and two-sided α = 0.05, 30 evaluable participants per arm are required. Allowing for 15% attrition, 35 participants per arm (70 in total) will be randomized.
Study Design and Assessments Two-arm, parallel-group superiority trial with 1:1 allocation. Randomization is performed centrally by Karolinska Trial Alliance, stratified by FHA severity at baseline (severe: estradiol <80 pmol/L and LH <2.4 IU/L), with randomly varying block sizes. At the screening visit, all individuals complete the DIAMOND screening questions and the complete eating disorder module, with further modules after a positive screening question. Validated questionnaires (including EDE-Q, PSS-14, GAD-7, PHQ-9, WHO-5, ISI, IPAQ and FSFI-6) and blood sampling (LH, FSH, estradiol, T3 and other hormones) are performed at baseline and at 3, 6, 9 and 12 months, with gynecological follow-up by video or in person. A gynecological examination with transvaginal ultrasound is performed at 12 months.
Data and Sample Collection Questionnaire data are collected electronically via REDCap. Findings from the feasibility study (NCT07589868) and the qualitative interview study inform the final protocol. Participants contact the clinic if menstrual bleeding occurs, and serum progesterone is measured on cycle day 21, counting the first day of bleeding as day 1, to assess ovulation.
Outcome Measures The primary outcome is the proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above [threshold] nmol/L) within 12 months. Secondary outcomes include time to first ovulatory cycle, number of spontaneous cycles, sustained recovery (≥3 consecutive cycles), change in LH, FSH, estradiol and T3, ultrasound signs of ovarian activity, psychological symptoms and well-being, and adverse events.
Statistical Analysis The primary analysis follows the intention-to-treat principle and compares the proportion with at least one spontaneous ovulatory cycle between groups, with the risk difference and 95% confidence interval and logistic regression adjusted for the stratification factor. Missing primary outcome data are handled with multiple imputation, with complete-case and worst-case sensitivity analyses. Secondary menstrual outcomes are analyzed with time-to-event methods and longitudinal outcomes with methods for repeated measurements. A detailed statistical analysis plan will be finalized before database lock.
Ethical Considerations Informed consent is obtained from all participants. The project is approved by the Swedish Ethical Review Authority (Dnr 2023-05586-01, with amendments 2025-07620-02 and 2026-06250-02). The overall risk to participants is considered low, and adverse events are monitored throughout the study period.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Hedvig Engberg, MD PhD
- 电话号码:+46 08 123 795 02
- 邮箱:hedvig.engberg@ki.se
研究联系人备份
- 姓名:Anna Strandqvist, PhD
- 电话号码:+46 08 123 779 69
- 邮箱:anna.strandqvist@ki.se
学习地点
-
-
-
Stockholm、瑞典
- Kvinnohälsan Karolinska Universitetssjukhuset
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
- Women aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist
- amenorrhea for at least 3 months
- a history compatible with functional hypothalamic amenorrhea
- exclusion of other causes of amenorrhea
- able to read and understand Swedish
- access to an internet-enabled device and BankID
- written informed consent.
Exclusion criteria:
- Current anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion)
- severe psychiatric comorbidity requiring other or more intensive care, including psychosis
- insufficient Swedish proficiency
- other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Psychoeducational Intervention
Behavioral: HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months. |
HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months. |
|
有源比较器:Treatment as Usual (TAU)
Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months; access to the program offered after 12 months. |
Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with return of spontaneous menstrual bleeding within 12 months from baseline.
大体时间:Restoration of menstruation after 12 months of follow-up from baseline.
|
Proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above 13 nmol/L. [Time frame: 12 months]. |
Restoration of menstruation after 12 months of follow-up from baseline.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to spontaneous ovulatory cycles within 12 months from baseline.
大体时间:Baseline to 12 months
|
Time to first spontaneous ovulatory cycle; number of spontaneous cycles; sustained recovery (≥3 consecutive spontaneous cycles) |
Baseline to 12 months
|
|
Change in BMI within 12 months from baseline.
大体时间:6 and 12 months from baseline
|
Weight and height will be combined to report BMI in kg/m^2 |
6 and 12 months from baseline
|
|
Change in serum luteinizing hormone (LH)
大体时间:Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum luteinizing hormone (LH). |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in serum follicle-stimulating hormone (FSH)
大体时间:Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum FSH (IU/L). |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in serum estradiol (E2)
大体时间:Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum estradiol (pmol/L), sensitive LC-MS/MS method. |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in serum triiodothyronine (T3)
大体时间:Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum T3 ([nmol/L or pmol/L, if free T3 - check with the laboratory]). |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in eating disorder symptoms (EDE-Q)
大体时间:Baseline to 12 months
|
Change from baseline in Eating Disorder Examination Questionnaire 6.0 global score (range 0-6; higher scores indicate more symptoms). |
Baseline to 12 months
|
|
Change in perceived stress (PSS-14)
大体时间:Baseline to 12 months
|
Change from baseline in Perceived Stress Scale total score (range 0-56; higher scores indicate more stress). |
Baseline to 12 months
|
|
Change in anxiety symptoms (GAD-7)
大体时间:Baseline to 12 months
|
Change from baseline in GAD-7 total score (range 0-21; higher scores indicate more anxiety). |
Baseline to 12 months
|
|
Change in depressive symptoms (PHQ-9)
大体时间:Baseline to 12 months
|
Change from baseline in PHQ-9 total score (range 0-27; higher scores indicate more depressive symptoms). |
Baseline to 12 months
|
|
Change in well-being (WHO-5)
大体时间:Baseline to 12 months
|
Change from baseline in WHO-5 percentage score (range 0-100; higher scores indicate better well-being). |
Baseline to 12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2023-05586-01
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
What data will be shared:
De-identified individual participant data collected during the trial, including:
Demographics (age, sex) Clinical assessments and questionnaire responses Hormonal measurements (LH, estradiol, progesterone) Menstrual cycle and ovulation data Psychological and behavioral assessments
Other documents to be shared:
Data dictionary describing all variables and coding used Study protocol and statistical analysis plan
IPD 共享时间框架
When data will become available and for how long:
Data will be available 6 months after publication of the primary trial results and will remain accessible for 5 years.
IPD 共享访问标准
By what access criteria:
Data will be available to qualified researchers for scientific purposes following submission of a research proposal and approval by the trial steering committee. Requests should be sent to the corresponding author or data custodian (contact information provided in the study publication).Data will be shared via a secure data repository
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.